- Home
- PETS vs CLRB Comparison
PETS vs CLRB Comparison
Compare PETS & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- CLRB
- Stock Information
- Founded
- PETS 1996
- CLRB 2002
- Country
- PETS United States
- CLRB United States
- Employees
- PETS N/A
- CLRB N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- CLRB Health Care
- Exchange
- PETS Nasdaq
- CLRB Nasdaq
- Market Cap
- PETS 68.6M
- CLRB 17.6M
- IPO Year
- PETS N/A
- CLRB N/A
- Fundamental
- Price
- PETS $3.32
- CLRB $4.88
- Analyst Decision
- PETS Sell
- CLRB Hold
- Analyst Count
- PETS 2
- CLRB 2
- Target Price
- PETS $3.35
- CLRB N/A
- AVG Volume (30 Days)
- PETS 124.8K
- CLRB 198.9K
- Earning Date
- PETS 08-05-2025
- CLRB 08-12-2025
- Dividend Yield
- PETS N/A
- CLRB N/A
- EPS Growth
- PETS N/A
- CLRB N/A
- EPS
- PETS 0.02
- CLRB N/A
- Revenue
- PETS $247,010,000.00
- CLRB N/A
- Revenue This Year
- PETS N/A
- CLRB N/A
- Revenue Next Year
- PETS N/A
- CLRB N/A
- P/E Ratio
- PETS $199.84
- CLRB N/A
- Revenue Growth
- PETS N/A
- CLRB N/A
- 52 Week Low
- PETS $2.90
- CLRB $4.36
- 52 Week High
- PETS $6.85
- CLRB $94.50
- Technical
- Relative Strength Index (RSI)
- PETS 42.37
- CLRB 34.07
- Support Level
- PETS $3.32
- CLRB $4.62
- Resistance Level
- PETS $3.49
- CLRB $5.05
- Average True Range (ATR)
- PETS 0.15
- CLRB 0.88
- MACD
- PETS 0.01
- CLRB -0.35
- Stochastic Oscillator
- PETS 51.35
- CLRB 8.92
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.